Rhinovirus

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

Absolute Biotech Relaunches SCICONS™ dsRNA Antibodies and ELISA Kits

Retrieved on: 
Thursday, July 20, 2023

BOSTON, July 20, 2023 /PRNewswire-PRWeb/ -- Absolute Biotech, a new company uniting multiple antibody-centric brands into a single organization specializing in antibody reagents, kits and services, today announced the reintroduction of SCICONS™ dsRNA antibodies. Originally developed in 1990, SCICONS antibodies have become the gold standard in double-stranded RNA detection, with hundreds of peer-reviewed citations characterizing their use in a diverse range of applications. The antibodies are now available to scientists worldwide through Absolute Biotech, with offerings including the original clones, ELISA kits and recombinant engineered antibody formats.

Key Points: 
  • BOSTON, July 20, 2023 /PRNewswire-PRWeb/ -- Absolute Biotech , a new company uniting multiple antibody-centric brands into a single organization specializing in antibody reagents, kits and services, today announced the reintroduction of SCICONS™ dsRNA antibodies.
  • The antibodies are now available to scientists worldwide through Absolute Biotech, with offerings including the original clones, ELISA kits and recombinant engineered antibody formats.
  • In addition to the original mouse monoclonal antibodies, Absolute Biotech offers the antibodies packaged into ELISA kits as well as recombinantly produced formats.
  • You can learn more about the SCICONS™ dsRNA antibodies and ELISA kits here .

Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent

Retrieved on: 
Tuesday, April 18, 2023

Neumifil, Pneumagen’s lead product, is being developed for the broad-spectrum prevention of viral induced exacerbations including those caused by influenza virus (IFV), respiratory syncytial virus (RSV), rhinovirus and coronavirus infections including COVID-19.

Key Points: 
  • Neumifil, Pneumagen’s lead product, is being developed for the broad-spectrum prevention of viral induced exacerbations including those caused by influenza virus (IFV), respiratory syncytial virus (RSV), rhinovirus and coronavirus infections including COVID-19.
  • Neumifil is currently being evaluated in a Phase 2a proof of concept challenge study in healthy participants subsequently infected with influenza virus.
  • Douglas Thomson, CEO of Pneumagen, commented: “This US patent grant is a key milestone for Pneumagen, which builds further significant value for Neumifil, our novel first in class host cell-targeted antiviral.
  • We are continuing to make excellent progress in developing this lead product and look forward to seeing further results from our clinical programme.

Altamira Therapeutics Provides Business Update

Retrieved on: 
Friday, January 27, 2023

Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update on its strategic repositioning and important business developments.

Key Points: 
  • Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today provided a business update on its strategic repositioning and important business developments.
  • Similarly, the Company is striving to sell or partner its other legacy assets – inner ear therapeutics.
  • Concurrently, Altamira is pursuing a divestiture or partnering transaction for the inner ear assets with other parties.
  • In the weeks and months ahead, we plan to update investors with news of our ongoing research findings and direction.”

RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments

Retrieved on: 
Wednesday, December 7, 2022

FARMINGTON, Conn., Dec. 07, 2022 (GLOBE NEWSWIRE) -- RIGImmune Inc., a biopharmaceutical company developing a new class of RNA immunotherapeutics, today announced new funding support from the Bill & Melinda Gates Foundation to advance the company’s RNA stem loop therapeutics platform for the treatment and adjuvancy of respiratory illnesses caused by RNA viruses. RIGImmune is one of the first development companies to receive an Accelerator Program-Related Investment (“PRI”) from the Bill & Melinda Gates Foundation Strategic Investment Fund. This new funding is additional to a Gates Foundation grant award that RIGImmune received last year to initiate its work in targeting its stem loop molecules for influenza to create broad spectrum host targeted antivirals.

Key Points: 
  • RIGImmune is one of the first development companies to receive an Accelerator Program-Related Investment (“PRI”) from the Bill & Melinda Gates Foundation Strategic Investment Fund .
  • This new funding is additional to a Gates Foundation grant award that RIGImmune received last year to initiate its work in targeting its stem loop molecules for influenza to create broad spectrum host targeted antivirals.
  • There is a significant and urgent unmet global medical need for the development of broad-spectrum antivirals against respiratory viruses.
  • The lead development candidate at RIGImmune is RIG-101 and the company is developing an intranasal formulation with the acquisition of antiviral company Subintro.

Helix & CDC Expand Partnership to Build First Ever Pan-Respiratory Viral Surveillance Program

Retrieved on: 
Thursday, December 15, 2022

SAN MATEO, Calif., Dec. 15, 2022 /PRNewswire/ -- Helix, the leading population genomics and viral surveillance company in the nation, today announced a new Broad Agency Announcement (BAA) contract awarded by the Centers for Disease Control and Prevention (CDC) to build a pan-respiratory viral surveillance program that standardizes linkage of viral sequencing data to key clinical and demographic data across a multi-site network. As part of the program, Helix will be partnering with HealthPartners, an integrated health care organization based in Bloomington, Minnesota of more than 1,800 physicians that serves more than 1.2 million patients, and Providence, a Renton, Washington-headquartered health care system of 25,000 physicians serving nearly 2 million covered lives across seven states with 28.1 million patient visits annually. This new agreement builds upon the partnership between Helix and the CDC and brings in health systems as critical partners to prepare the nation for the next public health emergency and ensure that COVID-19 never happens again.

Key Points: 
  • Helix was awarded $5 million from the CDC to build a pan-respiratory viral surveillance "early warning" program that will identify and track over 30 respiratory viral variants (including SARS-CoV-2, influenza, RSV, rhinovirus, etc.)
  • along with de-identified EHR data, for up to 16,000 samples over one year using the Company's proprietary Viral Sequencing Respiratory Panel.
  • "The CDC and Helix, working with health care systems, are leading the way to monitor viral outbreaks and improve national pandemic readiness."
  • Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics.

Anna Jaques Hospital RNs Go Public with Concerns for Patient Safety Resulting from Lack of Needed Staff & Closure of Essential Services

Retrieved on: 
Tuesday, November 22, 2022

NEWBURYPORT, Mass., Nov. 22, 2022 /PRNewswire/ -- Registered nurses at Beth Israel Lahey Anna Jaques Hospital (AJH) are sounding the alarm about the safety of patient care at the facility due to the lack of needed staff in a number of departments and the recent decisions by the hospital administration to close essential services, including the decision last year to close the hospital's pediatric unit and the periodic closure of the hospital's Computer Tomography (CT) scanning service. 

Key Points: 
  • In response, nurses report that hospital management has done nothing to address the conditions, which have only gotten worse.
  • "We were also concerned that while the CT service was closed, the public and our patients were not informed of that fact," Carbone said.
  • After a public hearing on the closure, the state's Department of Public Health, deemed the service "essential" for the health of the community.
  • To date, AJH's administration has turned a deaf ear to the nurses' concerns and their efforts to address the nurses' concerns.

Combined impact of flu and COVID-19 expected to continue to plague U.S. businesses this winter

Retrieved on: 
Thursday, November 3, 2022

PARSIPPANY, N.J., Nov. 3, 2022 /PRNewswire/ -- Analysis by Reckitt's Lysol Pro Solutions, a science-led business to business offering, in partnership with BlueDot Inc., the leading artificial and human intelligence organization for detecting, assessing, and responding to global infectious diseases, indicates a potentially severe season of respiratory viruses this winter in the U.S.

Key Points: 
  • Continued increase in air travel following the pandemic is likely to increase the spread of both cold and flu as well as COVID-19.
  • It's important that everyone - both businesses and citizens - play a role in helping to combat the spread of respiratory diseases.
  • "U.S. businesses are likely to be hit hard by the impact of a severe respiratory virus season, impacting worker productivity.
  • It is reasonable to expect that the timing of flu peaks throughout the rest of this season will be similarly unpredictable.

Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022

Retrieved on: 
Monday, October 24, 2022

GARDEN CITY, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced positive data from the LungFit® PRO pilot study of high-concentration inhaled NO in Viral Community-Acquired Pneumonia (VCAP), including COVID-19.

Key Points: 
  • The Company has received FDA approval for its first system, LungFit PH for persistent pulmonary hypertension of the newborn.
  • Nitric Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions.
  • Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia.
  • In adults, viruses have been identified as the causative agents in approximately 100 million cases of community-acquired pneumonia per year.